TR-412
/ Tarapeutics Science
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
March 26, 2025
Preclinical study of TR-412, a novel and highly selective CLK inhibitor for acute myeloid leukemia
(AACR 2025)
- "In particular, complete tumor regression was achieved in the MV4-11 tumor model. Overall, the preclinical findings strongly support that this novel CLK inhibitor TR-412 is worthy of further exploration in hematologic malignancies."
Preclinical • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Oncology • CDK1 • CLK2
1 to 1
Of
1
Go to page
1